Goldman Sachs Motif Human Evolution
ALTAR
Score™
1.0% info Recommen-
dation
AVOID
2019E    2020E
P/E
ratio
91.3x P/Sales
ratio
3.7x
P/BV
ratio
3.6x Div.
yield
1.0%


  • Description
  • Performance
  • Comps
  • premium Fundamentals
  • premium Valuation
  • premium Rating
Seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the Motif Human Evolution Index.

FUND BASICS
Category Global Equities
Fund Sponsor Goldman Sachs
Website www.gsam.com
Inception date Mar 01, 2019
Assets (mns) $9
Currency USD
Expense ratio 50 bp
Distributions Quarterly

FUND STRUCTURE
Regulation Open-Ended Fund
Custodian
Weighting Market Cap
Index replication
Uses derivatives No
Options available No

SECTOR BREAKDOWN

 


CONSTITUENT BREAKDOWN
No. of constituents 120
Wgt avg mkt cap (mns) $58,025
Large cap (>$10bn) 62.7%
Mid cap ($2-10bn) 18.8%
Small cap (<$2bn) 16.9%
Developed mkts 99.2%
Emerging mkts 0.8%

TOP TEN HOLDINGS
INTUITIVE SURGICAL INC 4.6 %
MEDTRONIC PLC 4.3 %
ABBOTT LABORATORIES 3.6 %
BOSTON SCIENTIFIC CORP 2.9 %
ROCHE HOLDING AG-GENUSSCHEIN 2.7 %
FRESENIUS MEDICAL CARE AG & 2.6 %
ASTRAZENECA PLC 2.6 %
JOHNSON & JOHNSON 2.6 %
BEIGENE LTD. SPONSORED ADR 2.2 %
ALIGN TECHNOLOGY INC 2.2 %
Total 30.5 %

TOP COUNTRY EXPOSURE
UNITED STATES 64.7 %
GERMANY 6.5 %
BRITAIN 5.8 %
SWITZERLAND 5.8 %
IRELAND 4.8 %
CHINA 4.0 %
FRANCE 2.2 %
JAPAN 2.1 %
NETHERLANDS 1.9 %
LUXEMBOURG 0.7 %

HISTORICAL PERFORMANCE info

  Custom date range Compare to  
  thru


Standardized Annual Returns (thru October 31)
Year-to-date 1 year 5 years 10 years Since Incep.
1.8% -- -- -- 1.8%

Market Correlations
versus... Beta R-squared
S&P500 -- --
MSCI EAFE -- --
MSCI Emg. Mkts. -- --

Technical Indicators
Recent close $53.23
30d moving avg. $50.43
Annualized volatility 0.0%
Short interest (ETF) 1.5%
Relative strength (RSI) 72

Liquidity measures
Avg. volume (thou.) 1
Turnover 0.6%
Bid/Ask (% of price) 0.13%
ADV underlying (mns) $11,171

Distributions


FINDING ALTERNATIVE FUNDS

Below is a list of 20 potential alternatives to the Goldman Sachs Motif Human Evolution ETF based on the alternatives' overlap in portfolio holdings with GDNA. Consider funds with lower expense ratios and/or higher ALTAR Score™ ratings as possible alternatives.

Benchmark ticker: GDNA Expense: 50 bp ALTAR Score™: 1.0%


ALTERNATIVE ETFs BASED ON OVERLAP WITH GDNA
Ticker Fund
Name
Overlap1
vs GDNA
(%)
Expense
ratio
(bp)
Savings
vs GDNA
(bp)
ALTAR
Score™
(%)
ALTAR
vs GDNA
(%)
IXJ iShares S&P Global Healthcare 35.5 46 4 6.5 +5.5
IEHS iShares Evolved U.S. Healthcare Staples 32.4 18 32 6.0 +5.0
FHLC Fidelity MSCI Health Care 29.9 8 42 6.0 +5.0
VHT Vanguard Health Care 29.4 10 40 6.0 +5.0
IYH iShares US Healthcare 29.4 43 7 6.5 +5.5
JHMH John Hancock Multifactor Health Care 29.1 40 10 6.8 +5.8
RYH Invesco S&P Equal Weight Healthcare 28.9 40 10 7.2 +6.2
XLV Health Care Select Sector SPDR 28.7 13 37 7.4 +6.4
IHI iShares DJ US Medical Devices 28.1 43 7 3.8 +2.9
LNGR Global X Longevity Thematic 26.7 50 0 3.6 +2.7
FXH First Trust Health Care Alphadex 24.9 63 -13 7.2 +6.2
HTEC Robo Global Healthcare Technology and Innovation 22.8 68 -18 0.0 -1.0
XHE SPDR S&P Health Care Equipment 21.5 35 15 2.2 +1.2
IDNA iShares Genomics Immunology and Healthcare 21.2 47 3 -4.8 -5.8
BTEC Principal Healthcare Innovators Index 20.2 42 8 -4.5 -5.5
XBI SPDR S&P Biotech ETF 19.0 35 15 -5.0 -6.0
IBB iShares NASDAQ Biotechnology 18.2 47 3 1.3 +0.3
IEIH iShares Evolved U.S. Innovative Healthcare 16.0 18 32 4.8 +3.8
PTH Invesco DWA Healthcare Momentum 15.3 60 -10 -1.4 -2.3
BBC Virtus LifeSci Biotech Clinical Trials 14.0 79 -29 -14.3 -15.3

1Overlap is the percentage of holdings by weight that are identical. For example, if Fund A has a 2% position in Apple, Inc. (AAPL) and Fund B has a 5% position, their overlapping position in AAPL is 2%.

Content on this tab for subscribers only**

RESULTS & ESTIMATES

  2014 2015 2016 2017 2018 2019E 2020E
Sales per share ** ** ** ** ** ** **
Earnings per share ** ** ** ** ** ** **
Dividends per share info ** ** ** ** ** ** **
Book value per share ** ** ** ** ** ** **

 

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

OTHER FUNDAMENTAL METRICS

Long term EPS growth est. **%   Debt-to-equity **x
Asset turnover **%   Assets-to-equity **x

Return on equity

Revision activity*
*Six months ago = 100

Net margins

Compound annual growth rates

Content on this tab for subscribers only

VALUATION METRICS
  2018 2019E 2020E
Price-to-sales ** ** **
Price-to-earnings ** ** **
Price-to-cash flow ** ** **
Price-to-growth ** ** **
Price-to-book value ** ** **
Yield ** ** **

Historical valuation trends

Forward
multiple:
Goldman Sachs Motif Human Evolution
Relative
to:
S&P500 MSCI EAFE MSCI Emg. Mkts. Other ETF:

AVOID

Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant.

ALTAR Score™


Calculation of ALTAR Score™
Avg. Return on Equity 5.2 %
Divided by: Fwd. P/BV 3.5 x
Less: Expense ratio 50 bp
Equals: ALTAR Score 1.0 %
info More information on ALTAR Score™

MODERN PORTFOLIO THEORY info

CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS
COMPOSITE
RATING
1.39 CATEGORY
AVERAGE
1.54
 
The composite rating is a weighted average of analysts' consensus recommendations for individual ETF constituents, based on the following scale:

BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3.

Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation.
 

 

See RATING tab for calculation of ALTAR Score™
Risk & reward. Uses std. dev. as proxy for risk, ALTAR Score™ for return forecast.
Dividends paid by constituents to the fund. May differ from actual distributions to shareholders due to constituent changes, timing issues or other factors.
Monthly returns based on changes in price plus dividends. May differ from daily returns reported by funds. See below for standardized returns.